2013-04-11Duchesnay Inc., a Quebec pharmaceutical company, sets for international expansion following the FDA approval of its morning sickness medication Diclegis® for pregnant women. Diclegis® has been available in Canada for some years under the trade-mark Diclectin®.
2013-04-02We are proud to announce that the New-York International Legal Alliance Summit & Awards has selected Goudreau Gage Dubuc to receive a Rising Star Award. This award recognizes GGD as a leading intellectual property firm, which has demonstrated its ability to provide efficient services in complex deals and to gain new market shares.
2013-04-01On April 26 every year, the World Intellectual Property Organization (WIPO) celebrates the “World Intellectual Property Day”. It aims to increase people’s awareness and understanding of intellectual property contribution to the development of innovation and creativity.
2012-11-05BÉATRICE T. NGATCHA, Patent Agent in the chemical sector, is invited to present a conference entitled "Le brevet - Plus qu'une protection, un outil de commercialisation" at the Corporation de développement économique communautaire Rosemont-Petite-Patrie, on Wednesday, November 21, 2012, from 8 to 10 AM. You will find registration instructions and additional information on cdec-rpp.ca.
2012-09-19Mr. Charles Goyer, Patent Agent, has been nominated to the Steering Committee of the Mentorat bioSuccès network as the representative of the Board of Directors of Montréal InVivo.
2012-06-12Alain M. Leclerc was elected President of FICPI CANADA for a three-year term ending in 2015. The election was held during the April 2012 FICPI World Congress in Melbourne, Australia. He is assisted in his duties by a dedicated Council of five top notch professionals from other Canadian IP firms.
2012-06-11Julie Gauvreau and Isabelle Pelletier, Patent Agents, are speakers at the conference series Innover c’est bien… breveter c’est mieux! (Innovating is good... patenting is better). They will host the workshop held in Sherbrooke, on June 14, Le brevet – Démarches, frais et délais (Patent: process, fees dans deadlines). They will also co-host with Caroline Lefebvre from OPIC, the workshops Les différentes formes de propriétés intellectuelles (various forms of intellectual property) and Étude de cas – AUTOPAINT (Study Case : AUTOPAINT).
2012-05-16Goudreau Gage Dubuc is pleased to have achieved in 2011 the strongest percentage growth in patent application filings amongst the top 12 IP firms in Canada. GGD has increased its volume of patent application filings by 14.5% over 2010, despite a shrinking market. For the GGD team, client service is front and center and a key part of the success equation.
2012-04-02We are proud to announce that the New-York International Legal Alliance Summit & Awards has selected Goudreau Gage Dubuc to receive a Rising Star Award. This award recognizes GGD as a leading intellectual property firm, which has demonstrated its ability to provide efficient services in complex deals and to gain new market shares.
2012-03-28Goudreau Gage Dubuc is proud to announce the nomination of Chantal Desjardins and Isabelle Jomphe as Leading Trademark Professionals by the World Trademark Review 1000 - 2012 Edition. At the vanguard of the practice, Chantal Desjardins is a renowned practitioner in the fields of enforcement and litigation as well as prosecution and strategy. Me Jomphe is also selected as a strong expert successfully involved in trademark prosecution, strategy, and portfolio management.
2012-03-26Lumira Capital II Funds provide financial support in life science sector in Québec. Montréal InVivo is proud to announce the launch on March 26th of two funds, managed by Lumira Capital, to stimulate innovation in life sciences and healthcare industry in Québec. The Merck Lumira Biosciences Fund will invest predominantly in biotechnology (35M$) while the Lumira Capital II Fund (101 M$) will concentrate on biotherapeutics and medical devices in a more advanced stage of their development.
2012-01-16Our sincere congratulations to Enobia on its recent acquisition by Alexion, in a transaction of just over one billion dollars. Enobia's lead product Asfotase Alfa is a recombinant protein for the treatment of patients suffering from hypophosphatasia, a life-threatening genetic metabolic disease characterized by a defect in bone mineralization, for which there are currently no approved treatment options. Enobia is a rare example of a true success story in Canadan biotechnology! Goudreau Gage Dubuc is proud to have collaborated with Enobia and wishes them and Alexion much success in bringing this product to market.
2011-02-22On November 25, 2010, in a victory for Lundbeck Canada Inc. and its Danish parent H. Lundbeck A/S, clients of Goudreau Gage Dubuc, the Federal Court of Appeal dismissed three appeals by the generic drug makers Genpharm ULC, Apotex Inc. and Cobalt Pharmaceuticals Inc. from a Federal Court judgment prohibiting the Minister of Health from issuing Notices of Compliance to these companies for generic versions of the drug containing escitalopram for use as an antidepressant, until a patent owned by H. Luncbeck A/S expires.
2010-12-23Congratulations to the Montreal biopharmaceutical company Theratechnologies on recently receiving approval from the U.S. Food and Drug Administration (FDA) for their lead product EGRIFTATM. This is welcome news for many HIV-infected patients, as EGRIFTATM is the only treatment approved by the FDA to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies has good reason to be very proud - they are one of the very few Canadian biotechnology companies to successfully take a product from discovery all the way to market on their own. GGD is a proud collaborator of Theratechnologies and wishes them all the best in their continued success!
2010-10-20Goudreau Gage Dubuc is proud to announce the nomination of Me Chantal Desjardins as Leading Trademark Practitioner by Who's Who Legal: Canada 2010. Me Desjardins is currently one of the foremost trademark experts selected amongst the best practitioners in Canada. Nominees have been selected by Who's Who Legal based upon independent survey work and tight international criteria, with both general counsel and private practice lawyers worldwide.
2010-01-19Coming into effect on March 11, 2010, the Canadian Intellectual Property Office will generally grant to applicants, if justified, only one extension of time for a period of six months to reply to an Office Action. Beyond that period, the applicants will need to show exceptional circumstances to be granted an additional period of time.
2009-10-28We are pleased to announce that at the IPIC 83rd Annual Meeting held in St. John's, Newfoundland, Me Alain M. Leclerc was nominated member of Council for 2009-2011. This Canadian professional association is comprised of over 1,700 members from Canada and abroad. At the same meeting, Me Leclerc was appointed President of the IPIC Committee on Patent Agents Exam Revision. He is also IPIC Council Representative of the Patent Agents Examining Board.
2009-10-09The Québec Government will invest $122.77 million, including $30 million for Genome Québec, over the next three years to consolidate Québec’s position in biopharmaceuticals.
2009-07-29The Canadian Intellectual Property Office (CIPO) recently introduced a new online service for Canadian Applicants allowing the e-filing of PCT applications including the electronic submission of sequence listings. Based on changes to the PCT Administrative Instructions on July 1, 2009, such e-filing of PCT sequence listings results in considerable savings in PCT filing fees when filing large documents. Goudreau Gage Dubuc was the first Canadian firm to use this e-filing service and submit electronically, for Xenon Pharmaceuticals Inc., a PCT application and its sequence listing. Besides facilitating the filing of large documents, this new service brings significant savings to our clients.
2009-07-27Goudreau Gage Dubuc is proud to announce that Alain Dumont, Ph.D., has successfully completed the Patent Agent exams. Alain joimed GGD on January 9, 2006, and his intellectual property areas of practice are biotechnology and pharmaceutical areas. Click here to view his biography.
2009-05-26Goudreau Gage Dubuc is proud to announce the nomination of Charles Goyer as Member of the Board of Directors of Montréal InVivo for a mandate of two years. Montréal InVivo is the trade name for the life sciences and health technologies cluster of Metropolitan Montréal. This creative cluster is ranked 1st in Canada in terms of the number of research centers and total university research funding.
2009-05-19Congratulations to Chantal Desjardins, Co-Managing Partner of Goudreau Gage Dubuc, who was recently appointed on the Board of Directors of CEAD Diffusion (Centre des auteurs dramatiques), a non-profit organization established to develop and promote Québec and French-Canadian plays and playwrights.
2009-05-14The 9th Edition of the Genesis Awards Gala, organized by BIOQuébec and which recognizes outstanding achievement by companies and individuals that play a key role in the growth of Québec's biotech, health technology and life sciences industries, was presented in Montréal on May 14, 2009. During this gala, Goudreau Gage Dubuc, which sponsors the Innovation Award since 2001, proudly presented its prize to Medicago Inc. Medicago is a biotechnology company focused on developing protein-based vaccines and biopharmaceuticals.
GGD is continuing its growth as a specialized intellectual property firm. While the firm has been in operation for the past 40 years, the litigation group is brand new.
Mtre Greg Moore, the partner responsible for the litigation group, and Mtre Chantal Desjardins, who heads the trade-mark group and is the firm’s co-managing partner, recently scored an important victory for a client in the agri-food industry. The client was threatened with an interim injunction that would have forced it to remove several hundred thousand units of its product from store shelves. The Court rejected the request for the injunction, to the great relief of the client. According to Mtre Moore, "We’re working hard to develop a reputation as specialists in intellectual property litigation. We’ll get there thanks to the meticulous preparation of our files – preparation which is the result of close collaboration between our clients and our experienced in-house patent and trade-mark specialists."
GGD’s patent practice is also experiencing strong growth. We have 10 patent agents recognized by the Canadian Intellectual Property Office, which ranks us second in Quebec. According to Mtre Alain Leclerc, the partner responsible for the patent group and co-managing partner, "our attractiveness in the marketplace is responsible for our accelerating growth. Nevertheless, we focus our efforts on quality work and let our growth occur naturally."
Goudreau Gage Dubuc on Managing IP website : Goudreau Gage Dubuc are newcomers to the rankings. Goudreau Gage is a firm to watch and is already garnering high praise from clients. A US lawyer extolled the firm's virtues: "I love working with Goudreau. The firm has a personal touch that is really useful."